1-methylcyclopropyl 4-((2,6-difluoro-4-(2-(2-methoxyethylcarbamoyl)pyrimidin-5-yl)phenoxy)methyl)piperidine-1-carboxylate | 1204129-66-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 1-methylcyclopropyl 4-((2,6-difluoro-4-(2-(2-methoxyethylcarbamoyl)pyrimidin-5-yl)phenoxy)methyl)piperidine-1-carboxylate
• 英文别名: (1-Methylcyclopropyl) 4-[[2,6-difluoro-4-[2-(2-methoxyethylcarbamoyl)pyrimidin-5-yl]phenoxy]methyl]piperidine-1-carboxylate
• CAS: 1204129-66-7
• 化学式: C₂₅H₃₀F₂N₄O₅
• 分子量: 504.534
• InChiKey: NTKKWONAQYHBBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  36
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• [EN] 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY<br/>[FR] 4-PHÉNOXYMÉTHYLPIPÉRIDINES COMME MODULATEURS DE L'ACTIVITÉ DE GPR119
  申请人：IRM LLC

  公开号：WO2010006191A1

  公开（公告）日：2010-01-14

  The present invention provides compounds of Formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent; diseases or disorders associated with the activity of GPR119.

  本发明提供了一种具有I式化合物的药物组合物，以及使用这种化合物来治疗或预防与GPR119活性相关的疾病或紊乱的方法。
• 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY
  申请人：Epple Robert

  公开号：US20110190298A1

  公开（公告）日：2011-08-04

  The present invention provides compounds of Formula I, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent; diseases or disorders associated with the activity of GPR119.

  本发明提供了一种I型化合物，包括这种化合物的药物组合物以及使用这种化合物治疗或预防与GPR119活性相关的疾病或疾病的方法。
• GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING G PROTEIN-COUPLED RECEPTOR ACTIVITY
  申请人：Indiana University Research and Technology Corporation

  公开号：EP2568993A1

  公开（公告）日：2013-03-20
• JP2011527701A
  申请人：——

  公开号：JP2011527701A

  公开（公告）日：2011-11-04
• GLUCAGON SUPERFAMILY PEPTIDES EXHBITING G PROTEIN COUPLED RECEPTOR ACTIVITY
  申请人：Dimarchi Richard D.

  公开号：US20130116172A1

  公开（公告）日：2013-05-09

  Provided herein are glucagon superfamily peptides conjugated with GPCR ligands that are capable of acting at a G protein-coupled receptor. Also provided herein are pharmaceutical compositions and kits of the conjugates of the invention. Further provided herein are methods of treating a disease, e.g., a metabolic disorder, such as diabetes and obesity, comprising administering the conjugates of the invention.